DYDan Yang

Dan Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dan Yang has a total of 50 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Wei

    School of Life Sciences, Shanghai University, Shanghai 200444, China

    2 shared publications
  • Hongyan Wang

    State Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    2 shared publications
  • Weiyun Li

    State Key Laboratory of RNA Innovation, Science and Engineering, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China

    2 shared publications
  • Baokai Zhang

    School of Life Sciences, Shanghai University, Shanghai 200444, China

    1 shared publication
  • Chang Liu

    State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, University of the Chinese Academy of Sciences, Shanghai 200031, China

    1 shared publication
  • Chao Peng

    National Facility for Protein Science in Shanghai, Zhangjiang Lab, Shanghai 201210, China

    1 shared publication

Latest Publications

  • Targeting PID1 generates oxysterols to switch macrophage cell fates for improved antitumor immunity

    by Yuxiao Zheng, Qi Wang, Chen Dong, Qiong Wang, Mingshun Han, Haiqing Zhao, Shuang Wang, Longlong Chen, Xiaoli Zhang, Dan Yang, et al.

    Disordered cholesterol–oxysterol profiles are observed in the tumor microenvironment, yet their roles in tumor-associated macrophages (TAMs) remain underexplored. This study reveals that TAMs across human pan-cancers exhibit elevated phosphotyrosine interaction domain-containing protein 1 (PID1) expression and prominent immunosuppressive gene signatures. PID1 deficiency in myeloid cells upregulates low-density lipoprotein (LDL) receptor expression, thereby promoting LDL uptake and intracellular accumulation of free cholesterol and reactive oxygen species (ROS). Increased ROS drives cholesterol oxidation to generate the oxysterols 5α,6α-epoxycholesterol (5α,6α-EC) and 7β-hydroxycholesterol (7β-OHC), which inhibit mTOR–STAT6 signaling in macrophages. Pid1 deletion switches immunosuppressive macrophages toward an antitumor subtype that downregulates arginase 1 expression while upregulating proinflammatory cytokines, thereby potentiating CD8+ T cell-mediated immunosurveillance across multiple tumor types. Moreover, combination treatment with the oxysterol and chemotherapeutic agent 5-fluorouracil produces synergistically enhanced antitumor effects. Previous studies showed that cholesterol-derived oxysterols differentially regulate macrophage cell fates, with 25-OHC promoting the protumor and immunosuppressive phenotype of TAMs. Targeting PID1 reroutes cholesterol and ROS metabolism toward the production of 5α,6α-EC and 7β-OHC in TAMs, representing a promising immunometabolic strategy to restore antitumor immunosurveillance.


  • HIPK2 phosphorylates HDAC3 for NF-κB acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis

    by Fang Zhang, Linlin Qi, Qiuyun Feng, Baokai Zhang, Xiangyue Li, Chang Liu, Weiyun Li, Qiaojie Liu, Dan Yang, Yue Yin, et al.

    Although inflammation is critical for the clearance of pathogens, uncontrolled inflammation also contributes to the development of multiple diseases such as cancer and sepsis. Since NF-κB–mediated transactivation in the nucleus is pivotal downstream of various stimuli to induce inflammation, searching the nuclear-localized targets specifically regulating NF-κB activation will provide important therapeutic application. Here, we have identified that homeodomain-interacting protein kinase 2 (HIPK2), a nuclear serine/threonine kinase, increases its expression in inflammatory macrophages. Importantly, HIPK2 deficiency or overexpression could enhance or inhibit inflammatory responses in LPS-stimulated macrophages, respectively. HIPK2-deficient mice were more susceptible to LPS-induced endotoxemia and CLP-induced sepsis. Adoptive transfer of Hipk2+/− bone marrow cells (BMs) also aggravated AOM/DSS-induced colorectal cancer. Mechanistically, HIPK2 bound and phosphorylated histone deacetylase 3 (HDAC3) at serine 374 to inhibit its enzymatic activity, thus reducing the deacetylation of p65 at lysine 218 to suppress NF-κB activation. Notably, the HDAC3 inhibitors protected wild-type or Hipk2−/− BMs-reconstituted mice from LPS-induced endotoxemia. Our findings suggest that the HIPK2-HDAC3-p65 module in macrophages restrains excessive inflammation, which may represent a new layer of therapeutic mechanism for colitis-associated colorectal cancer and sepsis. Significance Multiple human diseases including cancer and sepsis are closely related to uncontrolled inflammation. However, there is not much success for clinical therapy to date by targeting specific inflammatory cytokines. Since NF-κB–mediated transactivation in the nucleus is pivotal downstream of various stimuli to induce inflammation, searching the nuclear-localized targets specifically regulating NF-κB activation will provide important therapeutic application. This study has found that HIPK2 restrains NF-κB activation through phosphorylating HDAC3 at serine 374 to inactive HDAC3 deacetylase activity, thus reducing the p65 deacetylation and suppressing inflammation. Our findings reveal a function of the HIPK2-HDAC3-p65 module in macrophages to restrain excessive inflammation, which may represent a therapeutic mechanism for inflammation-related diseases.


  • Open Access

    Enforced expression of Hoxa5 in haematopoietic stem cells leads to aberrant erythropoiesis in vivo

    by Dan Yang, Xiangzhong Zhang, Yong Dong, Xiaofei Liu, Tongjie Wang, Xiaoshan Wang, Yang Geng, Shumin Fang, Yi Zheng, Xiaoli Chen, et al.

    Hoxa5 is preferentially expressed in haematopoietic stem cells (HSCs) and multipotent progenitor cells (MPPs), and is more highly expressed in expanding HSCs. To date, little is known regarding the role of Hoxa5 in HSCs and downstream progenitor cells in vivo. In this study, we show that increased expression of Hoxa5 in haematopoietic stem cells leads to aberrant erythropoiesis in vivo. Hoxa5 differentially modifies the cell cycle of HSCs and lineage committed progenitor cells, depending on the cellular context. Hoxa5 drives HSCs, but not MPPs, through the cell cycle and arrests erythroid progenitor cells in G0 phase. Although the HSC pool shrinks after overexpression of Hoxa5, HSCs sustain the abilities of self-renewal and multipotency. In vivo, Hoxa5 has two effects on erythropoiesis: it causes a predominance of mature erythroid lineage cells and the partial apoptosis of erythroid progenitors. RNA-seq indicates that multiple biological processes, including erythrocyte homeostasis, cell metabolism, and a...